AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35379222
Drug: Pain neuroscience
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain neuroscience education (PNE) and exercise intervention, 6 weekly sessions plus one review session after 1 month.
Trial: 35379222
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received treatment as usual (TAU).
Trial: 32381795
Drug: Bubble Breath
RxNorm normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bubble Breath Play Therapy (BBPT)
Trial: 36286651
Drug: Bulevirtide monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bulevirtide monotherapy for 24 weeks (MYR202 study)
Trial: 36286651
Drug: Bulevirtide monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bulevirtide monotherapy and combination with PEG‐IFN for 48 weeks (MYR203 study)
Trial: 35395819
Drug: Core stability
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Core stability training (15 min) + conventional treatment (40 min/day, 5 times/week for 8 weeks)
Trial: 35395819
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (40 min/day, 5 times/week for 8 weeks)
Trial: 33639967
Drug: Tomato powder
RxNorm normalized name: Tomato
DrugBank: Tomato (DB10573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato powder (30 mg lycopene, 5.38 mg beta-carotene, 22.32 mg phytoene, 9.84 mg phytofluene)
Trial: 33639967
Drug: Lycopene supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lycopene supplement (30 mg lycopene)
Trial: 35648053
Drug: Interactive video
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive video games (IVGs) + traditional neurodevelopment treatment (TNT)
Trial: 35648053
Drug: Walking training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walking training + traditional neurodevelopment treatment (TNT)
Trial: 34612724
Drug: Blonanserin tablet
RxNorm normalized name: Blonanserin
DrugBank: Blonanserin (DB09223)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Blonanserin tablet (4 to 24 mg/day, orally administered twice daily for 52 weeks)
Trial: 34612724
Drug: Blonanserin tablet
RxNorm normalized name: Blonanserin
DrugBank: Blonanserin (DB09223)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Blonanserin tablet (DB-blonanserin group)
Trial: 34612724
Drug: Blonanserin tablet
RxNorm normalized name: Blonanserin
DrugBank: Blonanserin (DB09223)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Blonanserin tablet
Trial: 33302270
Drug: Pomegranate Seed
RxNorm normalized name: pomegranate seed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate Seed Powder (PSP) 5 g, twice daily for 8 weeks
Trial: 32416538
Drug: Point-of-care (POC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Point-of-care (POC) HCV antibody testing by peer outreach workers
Trial: 33710587
Drug: Topical 17-β-estradiol-3-phosphate
RxNorm normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical 17-β-estradiol-3-phosphate eye drops (0.05% twice daily)
Trial: 33710587
Drug: Topical 17-β-estradiol-3-phosphate
RxNorm normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical 17-β-estradiol-3-phosphate eye drops (0.1% morning, vehicle in the evening)
Trial: 33710587
Drug: Topical 17-β-estradiol-3-phosphate
RxNorm normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical 17-β-estradiol-3-phosphate eye drops (0.1% twice daily)
Trial: 33710587
Drug: Topical 17-β-estradiol-3-phosphate
RxNorm normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical 17-β-estradiol-3-phosphate eye drops and Vehicle
Trial: 35101086
Drug: Acupuncture therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture therapy combined with fluticasone propionate nasal spray
Trial: 35101086
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate nasal spray alone
Trial: 33126335
Drug: Oral fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral fluconazole 800 mg/day for 2 weeks, followed by 400 mg/day for 8 weeks and 200 mg/day for 42 weeks
Trial: 33126335
Drug: Oral fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral fluconazole 400 mg/day for 52 weeks
Trial: 33126335
Drug: No antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antifungal treatment
Trial: 35603772
Drug: Telehealth mindfulness-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telehealth mindfulness-based cognitive therapy (MBCT-PD)
Trial: 35835612
Drug: Intravenous chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous chemotherapy (IV)
Trial: 34579146
Drug: Nut consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nut consumption (30 g/d of walnuts, almonds, and hazelnuts)
Trial: 33828613
Drug: Nicotine Replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine Replacement Therapy (NRT) sampling
Trial: 34797440
Drug: Small blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small blood loss (SBL) < 200 ml (n = 404)
Trial: 34797440
Drug: Medium blood
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium blood loss (MBL) 200 ml ≤ IBL < 400 ml (n = 393)
Trial: 34797440
Drug: Large blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large blood loss (LBL) IBL ≥ 400 ml (n = 406)
Trial: 35241003
Drug: Adjunctive istradefylline
RxNorm normalized name: istradefylline
DrugBank: Istradefylline (DB11757)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjunctive istradefylline (20 mg/day, increasing to 40 mg/day)
Trial: 35241003
Drug: Control (levodopa-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (levodopa-containing medications only)
Trial: 34460155
Drug: L-DOPA therapy
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-DOPA therapy at the peak
Trial: 34460155
Drug: L-DOPA therapy
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-DOPA therapy at the outcome
Trial: 32232692
Drug: Ninjin'yoeito (NYT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ninjin'yoeito (NYT) 9.0 g/day
Trial: 33405340
Drug: Proglumetacin (tested
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proglumetacin (tested twice independently, with AC50 of 8.9 µM and 12.5 µM)
Trial: 32407216
Drug: Pemetrexed (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed (500 mg/m2, day 1) plus cisplatin (75 mg/m2, day 1)
Trial: 32407216
Drug: Vinorelbine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine (25 mg/m2, days 1 and 8) plus cisplatin (80 mg/m2, day 1)
Trial: 33983512
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg HBB intravenously
Trial: 35889746
Drug: Low-dose quadruple
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose quadruple therapy with bismuth (two capsules of Pylera® plus 250 mg each of tetracycline and metronidazole)
Trial: 35889746
Drug: Low-dose quadruple
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose quadruple therapy with Lactobacillus reuteri (Gastrus®), one tablet twice-a-day for 27 days
Trial: 33159999
Drug: Neuraminidase inhibitors
RxNorm normalized name: Neuraminidase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuraminidase inhibitors (NAIs) for influenza B treatment; specific dosage and duration not mentioned.
Trial: 33159999
Drug: Polymerase inhibitor
RxNorm normalized name: RNA polymerase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymerase inhibitor baloxavir in high-risk influenza B patients; specific dosage and duration not mentioned.
Trial: 32164439
Drug: Lung cancer
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung cancer screening (LCS) by low-dose computed tomography (LDCT)
Trial: 36385638
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) for anxiety
Trial: 32679568
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (normal daily physical activity)
Trial: 34162777
Drug: Pharmaceutical consultation
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical consultation targeting outpatients by a pharmacist
Trial: 34162777
Drug: Nonintervention (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonintervention (no pharmaceutical consultation)
Trial: 34784108
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (0.5 g single oral PZA)
Trial: 34784108
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (0.5 g single oral PZA)
Trial: 34290666
Drug: High-concentration oxygen
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-concentration oxygen treatment [FiO280 (8 L/min)] for 6 hours
Trial: 34290666
Drug: Low-oxygen treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-oxygen treatment [FiO230 (2 L/min)] for 6 hours
Trial: 32555939
Drug: Esmolol (0.5‐mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (0.5‐mg/kg bolus followed by infusion at 15 µg/kg/min)
Trial: 32555939
Drug: Saline (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (30 mL bolus and infusion)
Trial: 34933721
Drug: Transplanted cartilage
RxNorm normalized name: SHARK CARTILAGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transplanted cartilage tissue and implants
Trial: 34933721
Drug: Implants only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implants only
Trial: 34990776
Drug: Whole Breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole Breast Radiation Therapy (WBRT) with T-DM1
Trial: 34990776
Drug: Whole Breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole Breast Radiation Therapy (WBRT) with TH
Trial: 33012517
Drug: 1.5 ml
RxNorm normalized name: Humulin 70/30 1.5 ML Pen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 ml kg−1 caudal injection of 0.2% ropivacaine
Trial: 33012517
Drug: Injection pauses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection pauses during caudal block
Trial: 32029439
Drug: Intermediate-dose cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intermediate-dose cytarabine
Trial: 32029439
Drug: Conventional-dose cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Conventional-dose cytarabine
Trial: 32029439
Drug: Two courses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two courses of intermediate-dose cytarabine with daunorubicin or mitoxantrone
Trial: 35654569
Drug: Risk perception
RxNorm normalized name: Herceptin
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Risk perception of developing oral disease
Trial: 36253765
Drug: Citrus peel
RxNorm normalized name: CITRUS AURANTIUM PEEL OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrus peel extract (400 mg containing 0.1 mg of AUR and 3 mg of NAR)
Trial: 34022138
Drug: Nasal High-Flow
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal High-Flow Oxygen (NHFS) (40% O2, 40 L/min, 37 °C)
Trial: 34022138
Drug: Conventional Nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Nasal Cannula (5 L/min)
Trial: 33884929
Drug: Weekly pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly pain ratings
Trial: 33884929
Drug: Daily pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily pain ratings
Trial: 33884929
Drug: Weekly ratings
RxNorm normalized name: Aratinga erythrogenys feather extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly ratings compared to daily ratings
Trial: 33884929
Drug: Weekly ratings
RxNorm normalized name: Aratinga erythrogenys feather extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly ratings
Trial: 38753374
Drug: Antidepressant monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant monotherapy
Trial: 35613418
Drug: Topical ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical ganciclovir 0.15% ophthalmic gel (1 drop 3 times daily, n = 6 cats)
Trial: 35613418
Drug: Oral famciclovir
RxNorm normalized name: Famciclovir
DrugBank: Famciclovir (DB00426)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral famciclovir (90 mg/kg twice daily, n = 6)
Trial: 35613418
Drug: Topical artificial
RxNorm normalized name: COLOR,ARTIFICIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical artificial tear gel (1 drop 3 times daily, n = 4)
Trial: 32768690
Drug: 3-item self-reported
RxNorm normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-item self-reported measure of adherence to medication
Trial: 34010546
Drug: Concurrent Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent Training (CT) with 15% velocity loss (VL15)
Trial: 34010546
Drug: Concurrent Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent Training (CT) with 45% velocity loss (VL45)
Trial: 36331315
Drug: Inclisiran 284
RxNorm normalized name: INCLISIRAN 284MG/1.5ML INJ,SOLN,SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inclisiran 284 mg
Trial: 35945594
Drug: Rosa foetida
RxNorm normalized name: Ballota foetida extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosa foetida extract capsules
Trial: 32585581
Drug: Z5 (5
RxNorm normalized name: Zoledronic acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Z5 (5 mg/kg/day)
Trial: 32585581
Drug: Z10 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Z10 (10 mg/kg/day)
Trial: 33612438
Drug: Automated Self-Administered
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Automated Self-Administered 24-Hour Dietary Assessment Tool (ASA24-2016)
Trial: 33612438
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ASA24-2016 recalls and DHQ-II
Trial: 34258913
Drug: Atorvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (20 mg, every night for 4 weeks)
Trial: 34258913
Drug: Combined group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined group (evolocumab, 140 mg, once every 2 weeks on top of atorvastatin 20 mg per day)
Trial: 34258913
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Atorvastatin only)
Trial: 34284351
Drug: Caffeine 0
RxNorm normalized name: caffeine 0.65 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 0 mg/kg (placebo)
Trial: 34049837
Drug: Self-management intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management intervention (exercise + education) including bi-weekly supervised exercise sessions and 30 min of education for 16 weeks (8 weeks supervised + 8 weeks self-guided with phone coaching)
Trial: 34604969
Drug: Contrast-enhanced ultrasound
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast-enhanced ultrasound (CEUS) with 4.8 mL of SonoVue
Trial: 34232137
Drug: Randomized controlled
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized controlled trial of CDI treatment in children
Trial: 35970020
Drug: Corbevax (two‐dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corbevax (two‐dose schedule with 28 days of interval between doses)
Trial: 35970020
Drug: Corbevax with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corbevax with 750 µg of CpG1018
Trial: 33455117
Drug: Osteosarcoma cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteosarcoma cell lines MG63 and HOS with methylation inhibitor
Trial: 35485658
Drug: Therapeutic exercises
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic exercises with an instructor, low‐intensity laser therapy, and PLFEF
Trial: 32363972
Drug: Pre-infusion single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-infusion single-dose mesenchymal stem cells (1 × 10^6 cells/kg)
Trial: 35728875
Drug: Spartalizumab 400
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Spartalizumab 400 mg intravenously every 4 weeks plus dabrafenib 150 mg orally two times daily and trametinib 2 mg orally one time daily
Trial: 32675595
Drug: Heated intraperitoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heated intraperitoneal chemotherapy (HIPEC)
Trial: 34441967
Drug: Topical corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroid (triamcinolone 0.05%)
Trial: 33331846
Drug: Taxane chemotherapy
RxNorm normalized name: acetaminophen / oxycodone hydrochloride Oral Capsule [Taxadone]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxane chemotherapy with indoximod
Trial: 33331846
Drug: Taxane chemotherapy
RxNorm normalized name: acetaminophen / oxycodone hydrochloride Oral Capsule [Taxadone]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxane chemotherapy without indoximod (control)
Trial: 34181478
Drug: 372 mg
RxNorm normalized name: zinc oxide 0.00372 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 372 mg ISAVUSULF intravenous solution via nasogastric tube
Trial: 34181478
Drug: 372 mg
RxNorm normalized name: zinc oxide 0.00372 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 372 mg ISAVUSULF capsules for oral administration
Trial: 35711602
Drug: Intranasal Normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal Normal Saline (NS)
Trial: 34463032
Drug: Bempedoic acid
RxNorm normalized name: bempedoic acid
DrugBank: Bempedoic acid (DB11936)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bempedoic acid (240 mg/day, supratherapeutic dose)
Trial: 32398091
Drug: Cruciferous vegetables
RxNorm normalized name: Hydrogenated Vegetable Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cruciferous vegetables (4 servings, 300 g per day as a soup, 500-600 mL/day)
Trial: 33568343
Drug: Low-dose fractionated
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose fractionated radiation (LDFRT) with PD-L1/CTLA-4 inhibition
Trial: 32623230
Drug: Monthly income
RxNorm normalized name: Lincomed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly income supplement
Trial: 32623230
Drug: Bimonthly income
RxNorm normalized name: Lincomed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimonthly income supplement
Trial: 32841158
Drug: Sexuality education
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sexuality education program (four weekly 2-hour sessions)
Trial: 33524970
Drug: Silodosin 4
RxNorm normalized name: silodosin 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silodosin 4 mg once daily
Trial: 35077638
Drug: Muscle Energy
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muscle Energy (ME) treatment
Trial: 35077638
Drug: High-Velocity Low-Amplitude
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Velocity Low-Amplitude (HVLA) treatment
Trial: 35077638
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of post-first-treatment values to pre-second-treatment values
Trial: 36062735
Drug: Moving to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moving to Opportunity treatment (housing vouchers)
Trial: 32283078
Drug: Pedicled buccal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pedicled buccal fat pad (group A)
Trial: 35979900
Drug: Generic fidaxomicin
RxNorm normalized name: Fidaxomicin
DrugBank: Fidaxomicin (DB08874)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Generic fidaxomicin (test formulation)